# EDGAR Filing Document

**Accession Number:** 0001645666
**File Stem:** 0001140361-26-022310
**Filing Date:** 2026-5
**Character Count:** 2783
**Document Hash:** 8e88efa4773755f2416bc96a0e3ff0d2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-26-022310.hdr.sgml**: 20260521

**ACCESSION NUMBER**: 0001140361-26-022310

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260521

**DATE AS OF CHANGE**: 20260521

**EFFECTIVENESS DATE**: 20260521

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kezar Life Sciences, Inc.
- **CENTRAL INDEX KEY:** 0001645666
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 473366145
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38542
- **FILM NUMBER:** 261005788

**BUSINESS ADDRESS:**
- **STREET 1:** 4000 SHORELINE COURT, SUITE 300
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-822-5600

**MAIL ADDRESS:**
- **STREET 1:** 4000 SHORELINE COURT, SUITE 300
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

#### <br>

### FORM 15

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.**

#### 001-38543
Commission File Number

#### KEZAR LIFE SCIENCES, INC.

------

(Exact name of registrant as speciﬁed in its charter)

#### 4000 Shoreline Court, Suite 300

#### South San Francisco, CA 94080
(650) 822-5600

------

(Address, including zip code, and telephone number, including area code, of registrant's principal executive ofﬁces)

#### Common Stock, $0.001 par value per share

------

(Title of each class of securities covered by this Form)

**None**

------

(Titles of all other classes of securities for which a duty to ﬁle reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to ﬁle reports:

Rule 12g-4(a)(1) ☒

Rule 12g-4(a)(2) ☐

Rule 12h-3(b)(1)(i) ☒

Rule 12h-3(b)(1)(ii) Rule 15d-6 ☐

Rule 15d-22(b) ☐

<br> Approximate number of holders of record as of the certiﬁcation or notice date: <u>One</u>

Pursuant to the requirements of the Securities Exchange Act of 1934, Kezar Life Sciences, Inc. has caused this certiﬁcation/notice to be signed on its behalf by the undersigned duly authorized person. <br>

---

| | | |
|:---|:---|:---|
| Date: May 21, 2026 | **KEZAR LIFE SCIENCES, INC.** | **KEZAR LIFE SCIENCES, INC.** |
|  | By:  | /s/ Michael Hearne |
|  |  | Name: Michael Hearne |
|  |  | Title: Chief Financial Officer |

---

------